Loading clinical trials...
Loading clinical trials...
A Clinical Study Evaluating a Recombinant Adeno-Associated Virus Serotype 9 (rAAV9) Capsid Containing the Human Lysosome-Associated Membrane Protein 2 Isoform B (LAMP2B) Transgene (RP-A501; AAV9.LAMP2B) in Male Patients With DD
Conditions
Interventions
RP-A501
Locations
3
United States
University of California, San Diego
La Jolla, California, United States
University of Colorado
Aurora, Colorado, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Start Date
April 17, 2019
Primary Completion Date
March 24, 2025
Completion Date
March 24, 2025
Last Updated
March 3, 2023
Lead Sponsor
Rocket Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions